Compare KRRO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | IVVD |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 212.6M |
| IPO Year | 2019 | 2021 |
| Metric | KRRO | IVVD |
|---|---|---|
| Price | $12.67 | $0.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $21.50 | $10.00 |
| AVG Volume (30 Days) | 212.2K | ★ 3.4M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | $6,392,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | N/A | $44.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | 110.47 |
| 52 Week Low | $5.20 | $0.53 |
| 52 Week High | $17.35 | $3.01 |
| Indicator | KRRO | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 38.22 |
| Support Level | $11.81 | $0.53 |
| Resistance Level | $14.47 | $0.66 |
| Average True Range (ATR) | 1.45 | 0.05 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 24.60 | 11.68 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.